natgillin/translations-raw huggingface dataset:
Hertil kommer, at der forbigående er observeret en K70E-mutation i hiv-1 RT. Hiv-1isolater med K65R-mutationen har en lav grad af nedsat følsomhed over for abacavir, emtricitabin, tenofovir og lamivudin.
HIV-1 isolates with the K65R mutation have low-level reduced susceptibility to abacavir, emtricitabine, tenofovir, and lamivudine.
Baseret på teoretiske overvejelser kan DRV/COBI øge eksponeringen for glecaprevir og pibrentasvir.
Based on theoretical considerations DRV/COBI may increase the exposure to glecaprevir and pibrentasvir.
Interaktionsprofilen for darunavir afhænger af, om ritonavir eller cobicistat benyttes som farmakokinetisk forstærker.
The interaction profile of darunavir depends on whether ritonavir or cobicistat is used as a pharmacokinetic enhancer; therefore, there may be different recommendations for the use of darunavir with concomitant medicines.
Opbevares i den originale yderpakning med tørremiddel i beholderen for at beskytte mod fugt.
Store in the original package with desiccant inside the bottle in order to protect the tablets from moisture.
Hver filmovertrukket tablet indeholder 800 mg darunavir (som ethanolat), 150 mg cobicistat, 200 mg emtricitabin og 10 mg tenofoviralafenamid (som fumarat).
Each film-coated tablet contains 800 mg darunavir (as ethanolate), 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide (as fumarate).
Fortæl det til din læge, hvis du tager: - Amlodipin, diltiazem, disopyramid, felodipin, flecainid, mexiletin, nicardipin, nifedipin,
Tell your doctor if you take: - Amlodipine, diltiazem, disopyramide, felodipine, flecainide, mexiletine, nicardipine, nifedipine, propafenone, lidocaine, verapamil (for heart disease) as the therapeutic effect or side effects of these medicines may be increased.
Klinisk monitorering anbefales ved co-administration af Symtuza og clonazepam.
Clinical monitoring is recommended when co-administering Symtuza with clonazepam.
Det forventes ikke, at cobicistat inducerer CYP1A2, CYP3A4, CYP2C9, CYP2C19, UGT1A1 eller P-gp (MDR1).
Cobicistat is not expected to induce CYP1A2, CYP3A4, CYP2C9, CYP2C19, UGT1A1, or P-gp (MDR1).
Knogler, led, muskler og bindevæv almindelig artralgi, myalgi ikke almindelig osteonekrose
Musculoskeletal and connective tissue disorders common arthralgia, myalgia uncommon osteonecrosis
- Apixaban, edoxaban, rivaroxaban (blodfortyndende medicin), da virkningen eller bivirkningerne af disse lægemidler kan blive ændret.
- Bosentan (to treat high blood pressure in the pulmonary circulation) - Apixaban, edoxaban, rivaroxaban (to reduce clotting of the blood) as their therapeutic effect or side effects may be altered.
• nedsat appetit (anoreksi)
• tiredness (fatigue)
Dihydroergotamin Ergometrin
Dihydroergotamine Ergometrine
Samtidig brug af Symtuza med lovastatin og simvastatin er kontraindiceret (se pkt.
Concomitant use of Symtuza with lovastatin and simvastatin is contraindicated (see section 4.3).
Prækliniske data for darunavir viser ingen speciel risiko for mennesker vurderet ud fra konventionelle studier af sikkerhedsfarmakologi, toksicitet efter gentagne doser, genotoksicitet og karcinogenicitet.
Non-clinical data on darunavir reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.
Hver filmovertrukken tablet indeholder 800 mg darunavir (som ethanolat), 150 mg cobicistat, 200 mg emtricitabin og 10 mg tenofoviralafenamid (som fumarat).
Each film-coated tablet contains 800 mg of darunavir (as ethanolate), 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide (as fumarate).
Der henvises til ordinationsoplysningerne for darunavir og emtricitabin/ tenofoviralafenamid for yderligere oplysninger.
For more details, refer to the prescribing information of darunavir and emtricitabine/ tenofovir alafenamide.
Hvis du kaster op mindre end 1 time efter, du har taget lægemidlet, bør du tage en ny dosis Symtuza sammen med mad så hurtigt som muligt.
If you vomit within 1 hour of taking the medicine, another dose of Symtuza should be taken with food as soon as possible.
• tenofoviralafenamid, et hiv-lægemiddel, der kaldes en nukleotid revers-transkriptasehæmmer
• tenofovir alafenamide, an anti-HIV medicine known as a nucleotide reverse transcriptase inhibitor
Samtidig infektion med hepatitis B og/eller hepatitis C Der var utilstrækkelige farmakokinetiske data i de kliniske studier til at bestemme virkningen af hepatitis B- og/eller C-virusinfektion på farmakokinetikken af darunavir, cobicistat, emtricitabin eller tenofoviralafenamid (se pkt.
There were insufficient pharmacokinetic data in the clinical trials to determine the effect of hepatitis B and/or C virus infection on the pharmacokinetics of darunavir,cobicistat, emtricitabine, or tenofovir alafenamide (refer to sections 4.4 and 4.8).
Der skal udvises forsigtighed ved kombination af disse antineoplastika og Symtuza.
Caution should be exercised when combining one of these anti-neoplastic agents with Symtuza.
Der blev ikke observeret klinisk relevante ændringer i farmakokinetikken for tenofovir hos patienter med let eller moderat nedsat leverfunktion.
Clinically relevant changes in tenofovir pharmacokinetics in patients with hepatic impairment were not observed in patients with mild to moderate hepatic impairment.
Hvis der går mere end 12 timer efter det sædvanlige tidspunkt for indtagelse af en dosis, skal den glemte dosis springes over, og patienten skal fortsætte efter den sædvanlige behandlingsplan.
If a missed dose is noticed later than 12 hours of the time it is usually taken, it should not be taken and the patient should resume the usual dosing schedule.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse antimykotika, og plasmakoncentrationen af darunavir, cobicistat og/eller tenofoviralafenamid kan øges af disse antimykotika.
Based on theoretical considerations DRV/COBI is expected to increase these antifungal plasma concentrations, and darunavir, cobicistat and/or tenofovir alafenamide plasma concentrations may be increased by the antifungals.
Baseret på MH-test, justeret for bPI ved screening (ATV med rtv eller COBI, DRV med rtv eller COBI, LPV med rtv) Uge 48-vindue: Dag 295 - dag 378; uge 96-vindue: Dag 631 - dag 714
Based on MH test adjusting for bPI at screening (ATV with rtv or COBI, DRV with rtv or COBI, LPV with rtv)
Co-administration af Symtuza og dapoxetin er kontraindiceret.
Co-administration of Symtuza with dapoxetine is contraindicated.
(CYP3A-hæmning og/ellertransport)
(CYP3A inhibition and/or transport)
Der er rapporteret om immunreaktiveringssyndrom hos hiv-patienter behandlet med CART.
In HIV infected patients treated with CART, immune reactivation syndrome has been reported.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge koncentrationen af alfusozin (CYP3A4-hæmning)
DRV/COBI is expected to increase alfusozin concentrations (CYP3A4 inhibition)
(interval 38 - 1.456 x 10
6 cells/L (range 38 - 1,456 x 10
Der skal udvises forsigtighed ved samtidig brug af Symtuza og PDE-5-hæmmere til behandling af erektil dysfunktion.
Concomitant use of PDE-5 inhibitors for the treatment of erectile dysfunction with Symtuza should be done with caution.
Baseret på teoretiske overvejelser kan DRV/COBI øge plasmakoncentrationen af buprenorphin og/eller norbuprenorphin.
Based on theoretical considerations DRV/COBI may increase buprenorphine and/or norbuprenorphine plasma concentrations.
Der henvises til produktresuméet for cobicistat for yderligere oplysninger.
For more information consult the cobicistat Summary of Product Characteristics.
Den rapporterede tid til udbrud er imidlertid mere variabel og disse hændelser kan opstå mange måneder efter behandlingsstart (se pkt.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment (see section 4.4).
Symtuza bør ikke administreres samtidig med lægemidler, der indeholder tenofovirdisoproxil (som fumarat, fosphat eller succinat), lamivudin eller adefovirdipivoxil, der anvendes til behandling af HBV-infektion.
Symtuza should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate, phosphate or succinate), lamivudine, or adefovir dipivoxil used for the treatment of HBV infection.
Der blev observeret et lille fald i plasmakoncentrationen af methadon med ritonavir-boostet darunavir.
With ritonavir-boosted darunavir, a small decrease in methadone plasma concentrations was observed.
Disse omfatter: - forhøjet blodsukker og forværring af diabetes - muskelsmerter, muskelømhed eller muskelsvaghed; disse muskellidelser har i sjældne tilfælde været alvorlige - immunrekonstitutionsinflammatorisk syndrom (IRIS).
These are: - raised blood sugar and worsening of diabetes - muscle pain, tenderness or weakness.
Din læge vil muligvis foretage yderligere test. - Colchicin (gigtmiddel).
Your doctor might want to do some additional tests.
Efter administration af tenofoviralafenamid viste [
Following administration of tenofovir alafenamide, plasma [
Samtidig brug af Symtuza og disse lægemidler er kontraindiceret (se pkt.
The concomitante use of Symtuza with these medicinal products is contraindicated (see section 4.3).
Symtuza må ikke administreres samtidigt med lægemidler, der indeholder tenofovirdisoproxil (f.eks. fumarat, phosphat eller succinat), lamivudin eller adefovirdipivoxil, der anvendes til behandling af HBV-infektion.
Symtuza should not be administered concomitantly with medicinal products containing tenofovir disoproxil (e.g. fumarate, phosphate, or succinate), lamivudine, or adefovir dipivoxil used for the treatment of HBV infection.
- Clonazepam (til at hindre krampeanfald) - Østrogen-baseret prævention og hormonerstatningsbehandling.
- Oestrogen-based hormonal contraceptives and hormone replacement therapy.
Baseret på teoretiske overvejelser forventes (systemisk) dexamethason at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat.
Based on theoretical considerations (systemic) dexamethasone is expected to decrease darunavir and/or cobicistat plasma concentrations.
Studier af udviklingstoksicitet hos rotter og kaniner viste ingen teratogene virkninger.
No teratogenic effects were observed in rats and rabbit developmental toxicity studies.
Biotilgængeligheden for alle komponenterne i Symtuza var sammenlignelig med den, der sås, når darunavir 800 mg, cobicistat 150 mg og emtricitabin/tenofoviralafenamid 200/10 mg blev co-administreret som separate formuleringer.
The bioavailability of all components of Symtuza was comparable to that when darunavir 800 mg, cobicistat 150 mg, and emtricitabine/tenofovir alafenamide 200/10 mg were co-administered as separate formulations; bioequivalence was established following single-dose administration under fed conditions in healthy subjects (N = 96).
Samtidig brug af Symtuza og alfusozin er kontraindiceret (se pkt.
The concomitant use of Symtuza with alfusozin is contraindicated (see section 4.3).
- Prednison (kortikosteroid).
- Colchicine (antigout).
Tenofoviralafenamid udviste antiviral aktivitet i cellekultur mod alle hiv-1-grupper (M, N og O) herunder undertyperne A, B, C, D, E, F og G (EC50-værdierne var i intervallet fra 0,10 til 12,0 nM) og udviste stammespecifik aktivitet mod hiv-2 (EC50-værdierne var i intervallet fra 0,91 til 2,63 nM).
The EC50 values for tenofovir alafenamide were in the range of 2.0 to 14.7 nM. Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups (M, N, and O), including subtypes A, B, C, D, E, F, and G (EC50 values ranged from 0.10 to 12.0 nM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.91 to 2.63 nM).
Kombinationen af avanafil og Symtuza er kontraindiceret (se pkt.
The combination of avanafil and Symtuza is contraindicated (see section 4.3).
Til forskel fra ritonavir inducerer cobicistat ikke CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 eller UGT1A1.
Unlike ritonavir, cobicistat is not an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1.
Symtuza 800 mg/150 mg/200 mg/10 mg tabletter darunavir/cobicistat/emtricitabin/tenofoviralafenamid
Symtuza 800 mg/150 mg/200 mg/10 mg tablets darunavir/cobicistat/emtricitabine/tenofovir alafenamide
Hos kvinder, der fik darunavir/cobicistat i andet trimester af graviditeten, var de gennemsnitlige intraindividuelle værdier for Cmax, AUC24t og Cmin for totaldarunavir hhv. 49 %, 56 % og 92 % lavere i forhold til post partum.
In women receiving darunavir/cobicistat during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC24h and Cmin were 49%, 56% and 92% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC24h and Cmin values were 37%, 50% and 89% lower, respectively, as compared with postpartum.
Baseret på teoretiske overvejelser forventes clarithromycin at øge plasmakoncentrationen af darunavir og/eller cobicistat.
Based on theoretical considerations clarithromycin is expected to increase darunavir and/or cobicistat plasma concentrations.
Der henvises til produktresuméet for clarithromycin for den anbefalede dosis ved anvendelse til patienter med nedsat nyrefunktion.
For patients with renal impairment the Summary of Product Characteristics for clarithromycin should be consulted for the recommended dose.
Sekalealkaloider som f.eks. ergotamin, dihydroergotamin, ergometrin og methylergometrin til behandling af migrænehovedpine
Rifampicin to treat some infections such as tuberculosis Pimozide, lurasidone, quetiapine or sertindole to treat psychiatric conditions Ergot alkaloids like ergotamine, dihydroergotamine, ergometrine and methylergonovine to treat migraine headaches
Det forventes ikke, at cobicistat hæmmer CYP1A2, CYP2B6, CYP2C8, CYP2C9 eller CYP2C19.
Cobicistat is not expected to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2C19.
Symtuza er ikke blevet undersøgt hos patienter med nedsat nyrefunktion.
Symtuza has not been investigated in patients with renal impairment.
Hvis patienten kaster op mindre end 1 time efter indtagelse af lægemidlet, bør patienten tage endnu en dosis Symtuza sammen med mad så hurtigt som muligt.
In case a patient vomits within 1 hour of taking the medicine, another dose of Symtuza should be taken with food as soon as possible.
3 (interval
3 (range:
Det frarådes at co-administrere Symtuza med boceprevir.
It is not recommended to co-administer Symtuza with boceprevir.
- Buspiron, clorazepat, diazepam, estazolam, flurazepam, zolpidem og midazolam som injektion
- Buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, midazolam when used as an injection (medicines to treat trouble with sleeping or anxiety) - Metformin (to treat type 2 diabetes)
In vitro metabolisereres tenofoviralafenamid ikke af CYP1A2, CYP2C8, CYP2C9, CYP2C19 eller CYP2D6.
In vitro, tenofovir alafenamide is not metabolised by CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.
Co-administration af Symtuza og disse antiepileptika er kontraindiceret (se pkt.
Co-administration of Symtuza and these anticonvulsants is contraindicated (see section 4.3).
Ændringer i målinger af knoglemineraldensitet
Changes in measures of bone mineral density
Baseret på teoretiske overvejelser kan DRV/COBI øge plasmakoncentrationen af disse analgetika.
Based on theoretical considerations DRV/COBI may increase plasma concentrations of these analgesics.
Symtuza og artemether/lumefantrin kan anvendes uden dosisjusteringer.
Symtuza and artemether/lumefantrine can be used without dose adjustments; however, due to the increase in lumefantrine exposure, the combination should be used with caution.
Symtuza 800 mg/150 mg/200 mg/10 mg filmovertrukne tabletter darunavir/cobicistat/emtricitabin/tenofoviralafenamid
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets darunavir/cobicistat/emtricitabine/tenofovir alafenamide
Naturlægemidler Perikon (Hypericum perforatum)
Herbal products St. John's wort (Hypericum Perforatum)
4.5) - dabigatran, ticagrelor
simvastatin, lovastatin and lomitapide (see section 4.5) - dabigatran, ticagrelor
Hvis der opstår tegn og symptomer på alvorlige hudreaktioner, skal Symtuza straks seponeres.
Symtuza should be discontinued immediately if signs or symptoms of severe skin reactions develop.
Hvis indiceret, kan det være nødvendigt at indlede behandling af hepatitis B. Hos patienter med fremskreden leversygdom eller cirrose frarådes seponering, da forværring af hepatitis efter behandlingen kan føre til nedsat leverfunktion.
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
Navn og adresse på den fremstiller (de fremstillere), der er ansvarlig(e) for batchfrigivelse
Name and address of the manufacturer(s) responsible for batch release Janssen-Cilag SpA
6 celler/mm
6 cells/mm 3 (range
Symtuza er ikke blevet undersøgt hos patienter med nedsat leverfunktion.
Symtuza has not been investigated in patients with hepatic impairment.
Genotypebestemmelse bør være vejledende for brugen af Symtuza (se pkt.
Genotypic testing should guide the use of Symtuza (see sections 4.2, 4.4, and 5.1).
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse sedativa/hypnotika.
Based on theoretical considerations DRV/COBI is expected to increase these sedative/hypnotic plasma concentrations.
Baseret på teoretiske overvejelser forventes rifampicin at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat og/eller tenofoviralafenamid.
Based on theoretical considerations rifampicin is expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
var 23 % (interval: 7-45 %).
95-1,110), and median CD4+ % was 23% (range: 7-45%).
Tenofoviralafenamid hæmmer ikke CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 eller CYP2D6 in vitro.
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 in vitro.
5.1) eller med hiv-1 RNA ≥ 100.000 kopier/ml eller CD4+-celletal < 100 celler x 10
Symtuza should not be used in treatment-experienced patients with one or more DRV-RAMs (see section 5.1) or with HIV-1 RNA ≥ 100,000 copies/mL or CD4+ cell count < 100 cells x 10
Det skal du vide, før du begynder at tage Symtuza Sådan skal du tage Symtuza Bivirkninger
What Symtuza is and what it is used for What you need to know before you take Symtuza How to take Symtuza
Blødninger hos patienter med hæmofili
Bleeding in haemophiliac patients
Baseret på teoretiske overvejelser kan DRV/COBI øge plasmakoncentrationen af methadon.
Based on theoretical considerations DRV/COBI may increase methadone plasma concentrations.
Forsøgsdeltagere,
Subjects,
Baseret på teoretiske overvejelser forventes bosentan at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat.
Based on theoretical considerations bosentan is expected to decrease darunavir and/or cobicistat plasma concentrations.
Amiodaron, dronedaron, ivabradin, kinidin, eller ranolazin til behandling af visse hjertelidelser (f.eks. unormal hjerterytme) Carbamazepin, phenobarbital og phenytoin til forebyggelse af krampeanfald Colchicin (hvis du har nyre-/leverproblemer)
Carbamazepine, phenobarbital and phenytoin to prevent seizures Colchicine (if you have kidney/liver problems) to treat gout The combination product lopinavir/ritonavir anti-HIV medicine
4.5) - rifampicin - sekalealkaloider (f.eks. dihydroergotamin, ergometrin, ergotamin, methylergometrin) - dapoxetin - domperidon - naloxegol - pimozid, quetiapin, sertindol, lurasidon (se pkt.
Co-administration with the following medicinal products due to the potential for serious and/or life-threatening adverse reactions (see section 4.5): - alfuzosin - amiodarone, dronedarone, ivabradine, quinidine, ranolazine - colchicine when used in patients with renal and/or hepatic impairment (see section 4.5) - rifampicin - ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - dapoxetine - domperidone - naloxegol - pimozide, quetiapine, sertindole, lurasidone (see section 4.5) - triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse neuroleptika.
Based on theoretical considerations DRV/COBI is expected to increase these neuroleptic plasma concentrations.
Baseret på teoretiske overvejelser kan DRV/COBI muligvis ændre plasmakoncentrationen af warfarin.
Based on theoretical considerations DRV/COBI may alter warfarin plasma concentrations.
(Induktion af CYP3A og/eller P-gp).
(CYP3A and/or P-gp induction).
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af digoxin.
Based on theoretical considerations DRV/COBI is expected to increase digoxin plasma concentrations.
(Hæmning af CYP3A og/eller P-glykoprotein).
(CYP3A and/or P-glycoprotein inhibition).
Baseret på teoretiske overvejelser forventes disse antimykobakterielle midler at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat og/eller tenofoviralafenamid.
Based on theoretical considerations these antimycobacterials are expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse kortikosteroider.
Based on theoretical considerations DRV/COBI is expected to increase these corticosteroid plasma concentrations.
Det frarådes at co-administrere Symtuza med bosentan.
Co-administration of Symtuza and bosentan is not recommended.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af salmeterol.
Based on theoretical considerations DRV/COBI is expected to increase salmeterol plasma concentrations.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af alfentanil.
Based on theoretical considerations DRV/COBI is expected to increase alfentanil plasma concentrations.
Tidligere ARV-svigt
It may harm them,
(Hæmning af CYP3A og/eller P-glykoprotein)
(CYP3A and/or P-glycoprotein inhibition)
(Induktion af CYP3A og/eller P-gp)
(CYP3A and/or P-gp induction)
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse immunsuppresiva.
Based on theoretical considerations DRV/COBI is expected to increase these immunosuppressant plasma concentrations.
4.5) - sildenafil til behandling af pulmonal arteriel hypertension, avanafil, simvastatin, lovastatin og lomitapid (se pkt.
see section 4.5) - sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil,
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af simeprevir.
Based on theoretical considerations DRV/COBI is expected to increase simeprevir plasma concentrations.
Baseret på teoretiske overvejelser kan DRV/COBI ændre plasmakoncentrationen af norethisteron.
Based on theoretical considerations DRV/COBI may alter norethindrone plasma concentrations.
Tabletkerne
30 tablets
Baseret på teoretiske overvejelser kan DRV/COBI øge eksponeringen for sekalealkaloider.
Based on theoretical considerations DRV/COBI may increase ergot derivative exposure.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af colchicin.
Based on theoretical considerations DRV/COBI is expected to increase colchicine plasma concentrations.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af metformin.
Based on theoretical considerations DRV/COBI is expected to increase metformin plasma concentrations.
- Fentanyl, oxycodon, tramadol (til smertebehandling) - Fesoterodin, solifenacin (til behandling af sygdomme i urinvejene).
- Fesoterodine, solifenacin (to treat urologic disorders).
- Rifabutin (mod bakterieinfektioner).
- Clonazepam (to prevent seizures).
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse antidepressiva.
Based on theoretical considerations DRV/COBI is expected to increase these anti-depressant plasma concentrations.